Ä¢¹½ÊÓƵ

MITSUBISHI CHEMICAL GROUP
MITSUBISHI CHEMICAL GROUP

MT-2766, Adjuvanted COVID-19 Vaccine Candidate,
Confirms Positive Efficacy and Safety Results from Phase 3 Study Conducted in an Environment Dominated by the Variants

December 7, 2021

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President: Hiroaki Ueno), an operating company of Mitsubishi Chemical Holdings Corporation (Head Office: Tokyo; President: Jean-Marc Gilson), announced today results of clinical trials for MT-2766, a COVID 19 vaccine candidate as follows.

Mitsubishi Tanabe Pharma¡¡Press Release


?Information is current as of the date of issue of the individual press release. Please be advised that information may be outdated after that point.

Back to top